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interview with dr. mark cockett: current
trends in screening for antiviral therapeutics 
Nina N. Brahmea and Devin J. Noblinb*
aDepartment of Cell Biology and bDepartment of Molecular, Cell, and Developmental 
Biology, Yale University School of Medicine, New Haven, Connecticut
Dr. Mark Cockett is vice President of Infectious Diseases and Applied Genomics at Bristol-
Myers Squibb (BMS†). In this interview, we ask Dr. Cockett about considerations that major
pharmaceutical companies such as BMS make when screening for and developing antivi-
ral small molecule therapeutics. we discuss the rationale behind an unbiased screening ap-
proach that led to recent published work identifying a hepatitis C-specific NS5A inhibitor.
we conclude by asking about the emerging role of academia in antiviral drug discovery and
future directions of pathogen drug discovery in general.
Dr. Mark Cockett is Vice President of
Infectious Diseases and Applied Genomics
at Bristol-Myers Squibb (BMS). The De-
partment of Infectious Diseases focuses on
HIV, hepatitis B, and hepatitis C. The De-
partment of Applied Genomics provides
genomic technologies and technology sup-
port to therapeutic areas across the com-
pany. Areas of support include new target
discovery, mechanism of action determina-
tion, and drug efficacy and liability evalu-
ation. The department also helps discover
biomarkers  to  support  clinical  develop-
ment.  
Before joining BMS, Dr. Cockett was
a research scientist at Celltech PLC, where
he obtained his PhD with Strangeways Re-
search Laboratory while studying matrix
metalloproteinases and tumor cell invasion.
He later was named Director of Molecular
and Cellular Biology in the Neuroscience
Department at Wyeth Pharmaceuticals.
What are a company’s major
decision-making processes
in selecting a
virus/pathogen to target?
As a company, we decided in 2002 to
focus on 10 disease areas; two of those
were viral: HIV and hepatitis. The decision
to focus on those areas was driven partly by
our expertise to use the skills that we have
and resources we could bring to bear right
here, partly by the company’s heritage and
partly by the future unmet medical needs
and market opportunities that exist in those
areas. Everything is driven by high, unmet
medical need disease areas on which we
focus our efforts, but we are a company, so
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in disease areas that get a return on our in-
vestments. Focusing on a small number of
areas is, I believe, one of the hallmarks of
what makes Bristol-Myers Squibb success-
ful today. You will see that we have deliv-
ered across the board in many of those areas,
and we have delivered a number of drugs
from our own research to the marketplace
and  have  a  pretty  healthy  late-phase
pipeline. We have launched 10 drugs in the
last seven years, and the majority of those
came from our own research. Of our late-
phase pipeline, drugs that we hope to regis-
ter or file in the next year or two, most are
from our own research as well. BMS has
been fortunate to have chosen to focus on
those areas, and they are areas in which we
are delivering across the board.
are there concerns about
screening targets against 
incomplete or biased 
compound libraries? What
classes/types of compounds
are you systematically 
missing in your current 
approach?
Pragmatically,  you  screen  what  you
can, and you follow up on what looks inter-
esting from the biology perspective. You
have compounds that have activities that
cross a threshold you set yourself, so you
want a certain potency and a certain chemi-
cal type that chemists feel are amenable to
medicinal chemistry. Chemical space is so
large that no one’s chemical libraries cover
all chemical space. I have heard that about
10
40 different chemicals would be needed to
fill the chemical space. In contrast, compa-
nies like ours have compound libraries of
only about 106 chemicals. Even if you have
all pharmaceutical companies’ drugs in one
library and screen them, you would still only
be sampling a fraction of chemical space.
You cannot sample all chemical space, and
everyone’s libraries are biased by the history
of how those libraries are created. You can-
not agonize over gaps in it. That being said,
what you can do is spend a lot of time as a
company carefully making sure the library
you do have is a good one. Given the limi-
tations or the history of how the library was
created, you can weed out compounds that
are unstable, toxic, cytotoxic, or bad starting
points for chemistry, and you can acquire
compounds proactively to add to your com-
pound deck that do have good properties.
You can use computer-aided technologies,
drug design-type technologies, to acquire
compounds in new chemical space that your
current library does not fill. So despite the
deficiencies of all of our libraries, you can
have a proactive program within your com-
pany to enhance the quality of your com-
pound  library.  That  is  really  important,
because if your compound library is not a
high quality one, you could end up chasing
down compounds that will never be devel-
opable. Or if you think your compound hit is
what is on the label and what is in the tube
is degraded, you must then work out what it
degraded to and what the activity is. Some-
times we do that, and it is very valuable, but
sometimes you spend a long time chasing
down a compound and find it is nothing of
interest or something you cannot work with.
So again, having a high quality compound
library is good, but you will never have a
perfect library, and it will always be biased
by the history of the company and how you
have built and acquired that library.
is it fair to say that any
classes/types of compounds
that you systematically miss
are omitted intentionally to
narroW doWn the pool of
relevant drugs?
We deliberately try to do that. Back in
the early 2000s, we went through a phase of
culling out from our library things that we
knew were going to be blind alleys, things
that we knew chemists would never follow
up on. When I worked at Wyeth, part of their
compound  library  heritage  came  from
American Cyanamid, a chemical manufac-
turer. All sorts of weed killers were in the li-
brary. Some were potentially developable, if
you modify them enough to be a pharma-
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that were good for weed killers but not good
for making drugs. Weeding those things out
(excuse the pun) was probably worthwhile.
If you are never going to follow up on them
as a human therapeutic agent or if there is
something you could never imagine follow-
ing up on because of the properties of the
molecules, you may as well weed them out
from the start and not have them in your
deck, so you save all that work and energy.
the recent nature paper by
min gao et al. [1] (from the
bms departments of 
virology, discovery medicine
and clinical pharmacology,
discovery chemistry, 
computer-aided drug design,
and metabolism and 
pharmacokinetics), in Which
the authors identified an hcv-
specific ns5a inhibitor, 
focused on unbiased 
screening of replication 
inhibitors and then pursuing
those acting through 
previously untargeted 
mechanisms. What is the 
reasoning behind that 
approach and hoW is it 
applied to other pathogens?
You can take two main approaches. One
is to look at the virus and understand the
genes in the virus and how it interacts with
the host and work out ways to rationally in-
hibit the virus. That is, focusing on viral
genes that encode enzymes, for instance,
such as proteases and polymerases. That has
been the mainstay of a lot of virology drug
development  over  the  years.  Nucleoside
drugs attack the polymerase active site in
HIV, HBV, and HCV. Non-nucleoside drugs
that  attack  the  polymerase  via  allosteric
binding sites also are used a lot in HIV. BMS
has Sustiva on the market, which is part of
the most popular HIV drug combination,
ATRIPLA, which mixes non-nucleoside and
two nucleoside inhibitors together as a triple
drug therapy, all targeting the polymerase.
BMS also has Reyataz, an inhibitor that tar-
gets HIV protease, on the market, as well as
a hepatitis drug, Entecavir, which is a nu-
cleoside inhibitor of the polymerase in hep-
atitis B. In all those targets, you can look at
the genetic code of the virus, understand that
there are some enzymes, do some biochem-
istry around those enzymes, rationally target
them with drugs to try to inhibit them, and
hope they do. The strength of this approach
is that you can identify enzymes, measure
them in tubes, and create assays to screen for
compounds very quickly. You can use crys-
tallography and X-ray crystal structures of
how the drugs bind to understand the inter-
action of the drug with the protein. You can
do a lot to rationally develop drugs and
leverage  a  lot  of  technologies  and  ap-
proaches. The downside, however, is that
you may not discover anything novel, and
everyone is working on the proteases and
polymerases, making it a very competitive
area. It’s difficult to be the first company out
with a drug in that class, and if you cannot
be first, you must try to come up with a drug
that can be best in class.
The advantage of going back to unbi-
ased screening is two-fold. First, you can dis-
cover new things, and second, anything you
get is active in a cellular assay right away. So
just to expand on that a little bit, the NS5A
inhibitor was discovered using a replicon
screen. The replicon is a replicating piece of
viral RNA that can be stably maintained in a
cell line and continues to replicate. We in-
corporate reporters such as luciferase, so that
the more replication going on, the more lu-
ciferase  signal  you  get.  You  can  screen
through the compound deck in a cellular
assay to look for inhibition of that signal, and
that can be miniaturized and done in really
high throughput. This particular assay was
run  through  a  high  throughput  screen  in
2001, and we got hits from that screen. The
hits were interesting chemicals that could in-
hibit the replicon that did not have any cyto-
toxic  effect  on  the  cell,  so  you  have  a
cytotoxicity index and an antiviral index.
You can basically say we have this set of hits
from this screen that look like they have
good antiviral effects and are not killing
cells; therefore, these might be good antivi-
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know what they do or how they are actually
working.  You  then  have  what  we  call  a
“mechanism of action” challenge: a proto-
type for a drug, or a starting point for a drug
program. But until you know more about
how they work in the cell and which targets
they are working through, rational drug de-
velopment is challenging because you are
just working with a cellular assay, and you
do not really know why and how it works. If
you just rely on those assays, you might get
misled. What you can do is essentially ge-
nomics, and you can select for resistance.
You can incubate your drug with replicon
cells, titrate the drug up to higher and higher
amounts of inhibitor, and essentially kill off
the replicon. You also can choose that the
replicon is in a cell with a selectable marker
such as neomycin. That way, you can insist
cells have to survive, have to have a replicon
in them with this selection marker, but you
can titrate up the replication inhibitor to a
point where the only thing that is going to
replicate is something that becomes resistant
to it. Select resistant colonies that contain
replicons resistant to your drug, and you can
isolate the replicon viral RNA and sequence
it,  asking  what  changed  from  before  the
treatment to after. Usually when you do this,
many things change, and you must home in
on which change in the virus was critical to
designate resistance. It could take some time
and many studies, but by doing so, you might
find that your drug is targeting a viral protein
with a point mutation that is resisting it. Once
you narrow it down to “the inhibitor might
inhibit this protein or that protein,” you can
then do biochemical and other sorts of assays
to firm up that finding and understand and
characterize it further. Through what is prob-
ably about two years of research going from
a screening hit to the target, you can charac-
terize and come up with a chemical inhibitor
of a new class of proteins. That is what hap-
pened with the NS5A inhibitor, and how you
get to the starting blocks to begin a program.
When you do that screen, you get a lot
of hits on different parts of the virus, you gen-
erate starting points for potentially several
programs, and you choose which one you
pursue, basically through a variety of mech-
anisms. Very often you are looking at which
drugs seem to be acting most reliably, which
chemicals look like the best starting points for
a chemist to conduct medicinal chemistry on,
and which mechanisms seem to shut down
the virus most effectively. The aggregate of
information generated around the drug activ-
ities makes you decide, “I am going to start
this program. It is around a particular protein
in the virus, and we are going to try to de-
velop the drug around that.” Instead of the
three- to five-year medicinal chemistry effort
to develop screening hits into a drug for a tra-
ditional  target,  this  process  takes  a  little
longer. For instance, our NS5A inhibitor dis-
covered in a high throughput screen in 2001
took until 2008 to reach human studies, and
we only started reporting our clinical data in
the last couple of years as we have started to
get some antiviral effects in patients. The first
bit sets you up for success, but it is a long haul
to improve the chemistry in getting potency,
viral genotype coverage, and drug-like prop-
erties into the molecules.
In virology, it is very important to con-
sider the spectrum of viruses for a given dis-
ease. When you think of viral disease, you
might think of HIV or hepatitis. There might
be one name for the virus, but in actuality,
there are many subviruses in that family. In
hepatitis, for example, there are genotypes
one through six, and within genotype one,
there are subtypes, 1a and 1b and so on, and
sometimes your early prototype drugs may
only work on one subtype. In the NS5A pro-
gram, our earliest prototype drug really only
worked on genotype 1b. It took years of
work to build in genotype 1a activity. Now,
our drug in the clinic has activity across all
six genotypes, and that was published in the
Nature paper, but to get to that point, it takes
years of research. You have to set yourself
up with a platform of viral or replicon assays
that represent the different genotypes and
sub-genotypes and routinely assay those and
develop them in parallel to understand the
potency of the drug. That is only one aspect,
however. You then need to build in proper-
ties of the drug, which make it stable and
safe in a human: potency, stability, lack of
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many other parameters important to develop
a drug. So that is why it takes so long.
What are some of the major 
strategies that your 
department employs to 
minimize the risk of 
mutational escape from neW
drugs?
Our first generation drugs are all driven
through just plain efficacy against the stan-
dard wild type viruses that exist for the given
strains. But we all know from the HIV expe-
rience that if you use a single drug in a pa-
tient,  you  will  generate  resistant  virus.
Hepatitis C is even worse. In hepatitis C, a
typical infected human produces 1012virions
a day, the polymerase makes a mistake 1 in
every 104 base additions, and the genome is
about 10,000 bases. So on average, every
virus has a mistake, and if you make 1012 per
day, there are 108 viruses with every given
mistake, which is pretty remarkable. What
this tells you is that you can mathematically
estimate that a patient harbors virus with
every pairwise combination of the mutant
you could possibly have. So the patient al-
ready has mutant virus in his system, and we
have to think about how we develop drugs to
overcome that. The current standard of care
in HIV drug discovery is to use three drugs
― you use three because even though the
virus might escape and become resistant to
one drug, it is statistically more difficult for
the virus to do the same with two and even
tougher  with  three.  Practically,  you  need
three drugs to completely suppress the virus
and not get resistance. We think it will be the
same with hepatitis C, where we are work-
ing on drugs with multiple mechanisms, we
are delivering those into clinical develop-
ment, and we are combining them to see if
they will have a higher barrier to resistance
together. So the first round in tackling viral
resistance is combination therapies.
Once  we  understand  what  resistance
looks like in a patient, because you do not re-
ally understand until you get your first drugs
in patients and you generate resistant virus
as part of those treatments, we recycle that
knowledge back from clinical development
into our research to enable us to develop im-
proved molecules. We take that information
back into the laboratory, and we generate re-
sistant viruses, and then we generate second
generation drugs that not only have potency
against wild type virus but also overcome the
resistance. In doing so, we generally develop
a drug with what we call a higher resistance
barrier. Once you understand what resistance
really looks like, you can rationally develop
second generation drugs that are improved
and maybe require more mutations to escape
the drug selection, essentially having better
drugs that you can potentially combine to
create a very high resistance barrier. That is
the approach we take: combination therapies
in the clinic to overcome resistance by using
multiple drugs with multiple mechanisms
and then following that up with higher re-
sistance barrier drugs.
What role do you see 
academia playing in the near
future regarding drug 
discovery and development?
is academia relegated to 
initial target identification?
Well, more and more, with various Na-
tional Institutes of Health (NIH) and uni-
versity funded projects, there are academic
screening centers being set up to go from
potential targets to potential drugs. One of
the more important results of this is that ac-
ademia in particular could spend time work-
ing on drug areas in which it is perhaps not
commercially viable for companies at this
point or areas that are too new and novel
that the risks are too high for pharmaceuti-
cal companies. So there are opportunities
for academic screening centers to comple-
ment what is done in industry and work on
screening  to  identify  chemical  starting
points for potential drug development in ad-
ditional areas. Academic screening centers
could be very good at identifying lead mol-
ecules to probe biology and understand bi-
ological mechanisms, but I am not sure they
have built the infrastructure required to take
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go through that five-year process. So there
is opportunity, as academic screening cen-
ters discover new chemical matter targeting
new proteins in new ways, to potentially
collaborate with industry and get into that
next stage. Going from a target to a com-
pound that is a chemical tool is still a long
way from a drug, and academic screening
centers are only at that first point right now.
But I certainly think there is a lot of activ-
ity, a lot more chemical space being probed
through academic screening centers.  
Many screening centers, however, use
similar chemical libraries, so the chemical
space being sampled could still be limited. It
probably would be advantageous to have all
the academic screening centers have comple-
mentary or different libraries, and you could
screen targets in a collaborative way, and that
way probe more chemical space. Or you po-
tentially could have screening centers that spe-
cialize in different target classes, for instance
ion channels or G-protein coupled receptors. 
Academic screening centers do tee up
potential tools to understand biology better,
and those tools turn around and help validate
targets more effectively. So tool generation
from academic screening centers is going to
benefit biological knowledge and potentially
spark collaborations with industry with in-
teresting chemical starting points. 
hoW do you see the field of
pathogen drug discovery
evolving over the next five
to 10 years?
Unbiased screening approach will com-
plement the rational approach of attacking
enzymes that you can work out through ra-
tional genomic approaches, structural biol-
ogy,  and  biochemistry.  Using  those
approaches,  you  also  uncover  potential
drugs that attack cellular proteins and help
the cell to fight the virus. Those are very dif-
ficult to track down, for example, because it
is tough to get resistance from a mammalian
cell, and if you do find that, it is difficult to
sequence a mammalian cell genome very ef-
ficiently and cheaply to be able to use ge-
nomics to uncover cellular targets. But I do
believe that with the advances in genomic
technologies, with newer sequencing tech-
nologies becoming less expensive, at some
point in the future, maybe another five years
or so, sequencing technologies will be at the
level at which you can sequence a whole
mammalian cell and find what changed in a
resistant cell and maybe home in on cellular
targets, too. So I think there will be several
approaches that will be used in parallel. We
will always go after an enzyme if we can ra-
tionally deduce that, because we know how
to do it effectively. We can always track
down an antiviral target using these genetic
approaches. The cellular targets are more
challenging, but I do believe we will be able
to discover them in the future.
The host immune system is another im-
portant factor. For instance, the current treat-
ment for an infected human with HIV or
hepatitis is immune stimulation with inter-
feron, and you can cure patients by stimulat-
ing the host immune system to fight the
virus. I do believe that as we understand that
more, we may be able to deliberately stimu-
late the immune system in specific ways to
fight different viral diseases. That is some-
thing that we are looking at and working on
now.
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